Rheumatology:抗SSA抗体阳性的SLE患者合并SS的可能性大

2013-11-07 xumanxiu dxy

抗SSA抗体阳性的SLE患者并发SS的可能性大干燥综合征(SS)的发病与系统性红斑狼疮(SLE)密切相关,迟发SLE的临床症状与SS相似。SLE合并SS的诊断常在诊断SLE或SS之后做出,且其系统损害更重。但是新发的SLE患者会不会并发SS、哪些临床表现或实验室指标有助于SLE并发SS的诊断尚不清楚。因此,来自多伦多大学的Gabriela等人对初发的SLE患者自身抗体表达及其合并SS情况进行研究,

抗SSA抗体阳性的SLE患者并发SS的可能性大

干燥综合征(SS)的发病与系统性红斑狼疮(SLE)密切相关,迟发SLE的临床症状与SS相似。SLE合并SS的诊断常在诊断SLE或SS之后做出,且其系统损害更重。但是新发的SLE患者会不会并发SS、哪些临床表现或实验室指标有助于SLE并发SS的诊断尚不清楚。因此,来自多伦多大学的Gabriela等人对初发的SLE患者自身抗体表达及其合并SS情况进行研究,研究结果发表在2013年8月份的《风湿病学》(Rheumatology)杂志上。该研究发现,年龄偏大的抗SSA抗体阳性的SLE患者易并发SS。【原文下载

该研究共纳入93名女性及10名男性初发的SLE患者,在入组前以及筛查SS时对所有患者进行抗Ro/SSA、抗La/SSB抗体及类风湿因子(RF)的检测。并分3个步骤进行以下项目的评估。初筛:欧洲调查问卷、滤纸试验、wafer检测;初步确诊:角膜荧光染色、无刺激下唾液流率检测、抗Ro/La等抗体测定;明确诊断:唇腺活检。如满足以下项目中2项或2项以上者可诊断为SS:欧洲调查问卷中至少有1项肯定答案,Wafer检测>4分钟,角膜荧光染色阳性,滤纸试验≤1.5ml/5分钟,抗Ro抗体或抗La抗体阳性。

结果显示,入组的初发SLE患者中,合并SS的共有19人(18.5%),均为女性。且年龄较未合并SS的患者大(P=0.004)。年龄≥25岁的、抗Ro/SSA抗体阳性的SLE患者合并SS的可能性大;而抗Ro/SSA抗体、抗La/SSB抗体及RF阴性的患者合并SS的可能性较小。

抗Ro/SSA抗体阳性的女性SLE患者合并SS的可能性大。而抗Ro/SSA抗体、抗La/SSB抗体及RF阴性的SLE患者合并SS的发生风险低。

原文出处

Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J, Nuñez-Alvarez CA, Cárdenas-Velázquez F, Hernández-Hernández C, Calderillo ML, Marroquín M, Recillas-Gispert C, Ávila-Casado C, Sánchez-Guerrero J.Predicting Sjögren's syndrome in patients with recent-onset SLE.Rheumatology (Oxford). 2013 Aug;【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1948092, encodeId=275c19480925c, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri Jun 13 01:08:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062486, encodeId=ade8206248696, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Jan 07 07:08:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746447, encodeId=8ab81e46447bc, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Sun Mar 16 21:08:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344887, encodeId=644f134488e6c, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Nov 09 05:08:00 CST 2013, time=2013-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1948092, encodeId=275c19480925c, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri Jun 13 01:08:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062486, encodeId=ade8206248696, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Jan 07 07:08:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746447, encodeId=8ab81e46447bc, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Sun Mar 16 21:08:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344887, encodeId=644f134488e6c, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Nov 09 05:08:00 CST 2013, time=2013-11-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1948092, encodeId=275c19480925c, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri Jun 13 01:08:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062486, encodeId=ade8206248696, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Jan 07 07:08:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746447, encodeId=8ab81e46447bc, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Sun Mar 16 21:08:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344887, encodeId=644f134488e6c, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Nov 09 05:08:00 CST 2013, time=2013-11-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1948092, encodeId=275c19480925c, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri Jun 13 01:08:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062486, encodeId=ade8206248696, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Jan 07 07:08:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746447, encodeId=8ab81e46447bc, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Sun Mar 16 21:08:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344887, encodeId=644f134488e6c, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Nov 09 05:08:00 CST 2013, time=2013-11-09, status=1, ipAttribution=)]